NCT06589830 2025-05-15TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal CancerSuzhou Teligene Ltd.Phase 2 Not yet recruiting80 enrolled
NCT02091141 2024-07-23My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid TumorsGenentech, Inc.Phase 2 Completed673 enrolled 22 charts
NCT04464967 2021-05-12Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersNKGen Biotech, Inc.Phase 1/2 Withdrawn
NCT00478140 2019-08-20Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by SurgeryNational Cancer Institute (NCI)Phase 2 Terminated4 enrolled 6 charts
NCT00005842 2013-02-11Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic CancerNational Cancer Institute (NCI)Phase 1 Completed24 enrolled
NCT00005926 2008-03-04Gemcitabine, Herceptin and Radiation to Treat Cancer of the PancreasNational Institutes of Health Clinical Center (CC)Phase 2 Completed50 enrolled